[ad_1]
It is the first vaccine candidate published in a peer-reviewed medical journal.
The results of the Pfizer and Biontech vaccines are published in the New England Journal of Medicine. The results of the test are known as a win.
Late Thursday night Norwegian time, the FDA expert panel also decided to recommend that Pfizer and Biontech’s coronary vaccine receive emergency approval in the United States.
The vaccine has already been approved in the UK and Canada, and the FDA panel meeting is the final step before shipping of millions of doses of the vaccine to the United States can begin.
The country’s health authorities are expected to follow the recommendation. A final decision is expected in a few days.
– a triumph
The results of the AstraZeneca vaccine and the University of Oxford were published in The Lancet on Tuesday as the first vaccine candidate in a peer-reviewed medical journal. Now Pfizer’s results have also been published.
– The test results are good enough to support every conceivable analysis. This is a triumph, it is said in the editorial review of the results.
Also Read: Mistake Made By Former Vaccine Favorite: – Surprising, Disappointing, and Confusing
The full clinical trial included nearly 44,000 test subjects. The article confirms after a peer review that the vaccine is 95 percent effective in preventing coronary heart disease.
Of ten people who developed a severe course of COVID-19 after the study, nine had received a placebo injection and one person had received the vaccine.
The sea
The modern vaccine has a great advantage
The low number of infections in the study means that it is not possible to conclude whether the rare cases of disease after vaccination can develop more severe courses.
As with other vaccines, it is also uncertain how long the vaccine provides immunity and what side effects can occur for long periods after the vaccine. (© NTB)
Advertising
Electric shock: spot price 53.49 øre – fixed price 4.90 øre
